Sector News

Sobi Names Holly May VP Sales and Marketing in United States

January 29, 2018
Life sciences

Sobi, a pioneering international biopharmaceutical company dedicated to rare and difficult-to-treat diseases, announced today that experienced commercial leader Holly May has joined the company as vice president of sales and marketing for the United States.

May will lead the commercial team in bringing Sobi’s multiple approved medicines to patients in the U.S. She will collaborate with the operations and patient access team to ensure the medicines Sobi provides are optimally accessible to as many appropriate patients as possible. Additionally, she will support the launch of new products in the U.S. derived from Sobi’s pipeline of proprietary medicines or from external sources of innovation.

May’s more than 20 years of experience in biopharmaceutical sales and marketing includes previous positions focusing on patients suffering from rare diseases. Most recently she served as vice president and head of U.S. marketing for Fabry disease and lysosomal storage disorders at Sanofi Genzyme, and prior to that she served as vice president and head of the U.S. Fabry disease, responsible for both the commercial activities and teams at Genzyme Corp. May held multiple sales and marketing positions during her 17 year career at Sanofi, including director of marketing operations and strategic planning for Sanofi’s Global Oncology Division and regional sales director for Sanofi’s cardiovascular business unit. Prior to joining Sanofi, May held various sales and marketing positions at DuPont Pharmaceuticals Co., DuPont Merck Pharmaceutical Co. and Endo LLC.

“Sobi has a 30 year legacy in the rare disease field, and globally we market 35 medicines across 67 countries. As we look to increase our footprint specifically in North America, where more than 33 million patients are estimated to suffer from a rare disease, Holly’s experience will be incredibly valuable,” said Rami Levin, president of Sobi in North America.

“I have been privileged to work in the rare disease field, leading commercial teams in providing education to patients, caregivers and physicians around important rare disease issues such as diagnosis, disease symptoms and treatment options, while always seeking to better understand the patient journey and improve the patient experience,” said May. “I look forward to applying my expertise to help Sobi bring its existing and future products to patients who need them.”

Source: Sobi

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.